Artac, M. Et Al. 2010. The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.136, no.6 , 803-809.

Artac, M., Bozcuk, H., PEHLİVAN, S., Akcan, S., PEHLİVAN, M., Sever, T., ... Ozdogan, M.(2010). The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.136, no.6, 803-809.

Artac, Mehmet Et Al. "The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.136, no.6, 803-809, 2010

Artac, Mehmet Et Al. "The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.136, no.6, pp.803-809, 2010

Artac, M. Et Al. (2010) . "The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.136, no.6, pp.803-809.

@article{article, author={Mehmet Artac Et Al. }, title={The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens}, journal={JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY}, year=2010, pages={803-809} }